TQB3122是一款具有高选择性和血脑屏障穿透能力的PARP1抑制剂，通过双重机制发挥抗肿瘤作用：一 方面，竞争性抑制PARP1酶的催化活性，阻断DNA单链断裂修复;另一方面，通过"捕获"机制稳定DNA- PARP复合物，阻碍复制叉进展。基于"合成致死"塬理，TQB3122可选择性杀伤BRCA 突变或同源重组 缺陷的肿瘤细胞。研究显示，TQB3122在多个肿瘤模型中疗效显著，且脑组织分布能力突出，是颅内肿 瘤治疗的潜在新选择。 目前，全球尚无同靶点药物获批上市。该集团将探索TQB3122在晚期实体瘤中的安全性与疗效，有望为 全球患者提供新的治疗选择。 智通财经APP讯，中国生物制药(01177)公布，该集团自主研发的创新药TQB3122"PARP1抑制剂"的新药 临床试验申请(IND)已获得中国国家药品监督管理局 (NMPA)受理，拟用于治疗晚期恶性肿瘤。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 目前，全球尚無同靶點藥物獲批上市。本集團將探索TQB3122在晚期實體瘤中的安全性與療效，有 望為全球患者提供新的治療選擇。 承董事會命 中國生物製藥有限公司 主席 謝其潤 香港，二零二五年八月十一日 1 （於開曼群島註冊成立之有限公司） 網站：www.sinobiopharm.com （股份編號：1177） 自願公告 TQB3122「PARP1抑制劑」臨床試驗申請獲NMPA受理 中國生物製藥有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事會（「董事會」）宣佈，本集團自 主研發的創新藥TQB3122「PARP1抑制劑」的新藥臨床試驗申請(IND)已獲得中國國家藥品監督管理局 (NMPA)受理，擬用於治療晚期惡性腫瘤。 TQB3122是一款具有高選擇性和血腦屏障穿透能力的PARP1抑制劑，通過雙重機制發揮抗腫瘤作 用：一方面，競爭性抑制PARP1酶的催化活性，阻斷DNA單鏈斷裂修復；另一方面，通過 ...

Summary of Boundless Bio (BOLD) Update / Briefing May 27, 2025 Company Overview - **Company**: Boundless Bio (BOLD) - **Focus**: Development of therapies for oncogene amplified cancers, particularly through the study of extrachromosomal DNA (e cDNA) biology [5][6] Key Industry Insights - **Industry Context**: The biotechnology sector is facing challenges in securing funding and establishing differentiation due to a proliferation of competitor compounds [38] - **Market Considerations**: The company is prioritizing first-in-class drugs against innovative biological targets to maintain a competitive edge [38] Core Points and Arguments 1. **Portfolio Prioritization**: Boundless Bio has decided to discontinue all current arms of the BBI-355 clinical trial due to clinical observations and market considerations, shifting focus to a new trial arm evaluating BBI-355 in combination with BBI-825 [3][4] 2. **Workforce Reduction**: The company has streamlined operations, reducing its workforce by approximately 20 positions, representing about one-third of its staff, to extend its cash runway into the first half of 2028 [4][36] 3. **Development Candidates**: BBI-940 has been declared a development candidate for the novel kinesin oral degrader program, with an IND filing expected in the first half of 2026 [4][36] 4. **Clinical Findings**: BBI-355 has shown evidence of anti-tumor activity but has a narrow therapeutic index due to on-target hematologic toxicity, leading to the decision not to advance certain clinical arms [12][14] 5. **Combination Therapy Rationale**: The combination of BBI-355 and BBI-825 is believed to provide synergistic anti-tumor activity while minimizing hematologic toxicity, with plans to initiate clinical development in 2025 [28][29] Additional Important Content - **Scientific Basis**: The company has developed a proprietary SpyGlass platform to identify new targets in e cDNA biology, leading to the discovery of three druggable targets that may be synthetic lethal in oncogene amplified tumors [5][6] - **Clinical Strategy**: The combination of BBI-355 and BBI-825 is expected to leverage the unique mechanisms of both drugs, potentially overcoming the limitations observed when each is used independently [20][28] - **Preclinical Data**: BBI-940 has demonstrated potent anti-tumor activity in preclinical models, with favorable pharmacokinetics and oral bioavailability [33][34] - **Future Outlook**: The company is focused on achieving important clinical readout milestones and believes it is uniquely positioned with proprietary selective inhibitors [39][70] Financial Guidance - **Cash Runway**: The changes in operations and portfolio prioritization are expected to extend the company's cash runway into the first half of 2028, aligning with anticipated clinical readouts [36][37]